Adaptimmune is a clinical-stage biotechnology company with clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. Adaptimmune partners with industry leaders in all areas of its business.
We are passionate about our SPEAR T-cell therapies, and we are always looking for the right technology partnerships to deliver for people living with cancer.
The Company has alliances with a range of partners listed below.
Adaptimmune has signed a co-development and co-commercialization agreement with Astellas, through its wholly-owned subsidiary Universal Cells, Inc, to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.View Partner
Our agreement with Cell and Gene Therapy Catapult enables us to have our own dedicated GMP (Good Manufacturing Practices) vector manufacturing space in the UK.View Partner
We signed a collaboration with the Center for Cancer Immune Therapy (CCIT-DK - based in Copenhagen) in 2020. CCIT is one of the leading academic centers in Europe involved in researching tumor infiltrating lymphocyte (TIL) therapies.View Partner
Adaptimmune has a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center signed in 2016 designed to expedite the development of novel adaptive T-cell therapies for multiple types of cancer.View Partner
Adaptimmune is working with Noile-Immune Biotech Inc. to co-develop next‑generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (PRoliferation Inducing and Migration Enhancing) technology.View Partner
Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited iPSC cell lines. In January 2020, Adaptimmune signed a further co-development and co-commercialization agreement to bring up to three new stem-cell derived allogeneic T-cell therapies to people with cancer.View Partner